FDA-peptidlisteafstemning: Hvad synteseteams skal dokumentere nu

Hvad juli 2026 Stem gjorde - og hvad den efterlod åben

Det rådgivende udvalg for apotekssammensætning mødtes i juli 23 og 24, 2026 at overveje syv peptider, der er nomineret til optagelse på 503En liste over stoffer i bulk — den bekræftende liste, der lader statsautoriserede læger og farmaceuter sammensætte ved hjælp af et bulkstof, der ikke har nogen anvendelig USP-monografi og ikke er en del af et godkendt lægemiddelprodukt. Under 21 CFR 216.23(c), FDA vurderer fire ting: fysisk og kemisk karakterisering af stoffet, sikkerhedsproblemer som følge af dets brug i sammensatte produkter, bevis for effektivitet eller fravær, og historisk brug i sammensatte stoffer.

FDA's karrierepersonale frigivet briefing dokumenter i juni 29, 2026 fraråder at tilføje nogen af ​​de syv. Udvalget stemte den anden vej om seks.

Stemmetæller som rapporteret af RAPS og andre forretninger, der dækker juli 2026 PCAC-peptidafstemning.

Hvad FDA har gjort: indkaldte udvalget, offentliggjorte orienteringsdokumenter, og modtog en rådgivende anbefaling om seks stoffer.

Hvad FDA ikke har gjort: tilføjet et hvilket som helst peptid til 503A bulkslisten, tilladt enhver sammensætning, eller godkendt ethvert produkt. Tilføjelse af et stof til listen kræver regler for meddelelse og kommentar, som ikke var afsluttet. Den regulatoriske status for alle syv peptider var uændret af stemmerne.

To yderligere fakta forhindrer, at dette er en lukket historie. FDA har annonceret et opfølgende rådgivende udvalgsmøde inden udgangen af ​​februar 2027 at gennemgå yderligere peptider, angiveligt inklusive GHK-Cu, melanotan II, cathelicidin (LL-37), dihexaacetat, og pegyleret mekanisk vækstfaktor. Og i juli 2026 FDA trak sin tilbage 2021 vejledning om højt oprensede syntetiske peptidlægemidler, der refererer til lægemidler med rDNA-oprindelse, siger, at det ikke længere afspejlede den nuværende videnskabelige tænkning, samtidig med at den har til hensigt at genudsende den. Rammerne bevæger sig, ikke afregne.

Den praktiske konsekvens for en synteseorganisation: det specifikke resultat af FDA-peptidlisten betyder langt mindre end den bevismæssige standard, der anvendes på peptidkvalitetsdata. Den standard er nu synlig i offentlige dokumenter, og det er den samme standard som et program vil stå over for, om det endelige spørgsmål er et sammensat andragende, en ny lægemiddelansøgning, eller en leverandørkvalifikationsaudit.

Hvorfor uenigheden mest handlede om papirarbejde

Læs FDA's briefingsmateriale, og et mønster dukker op, som er let at gå glip af i dækning med fokus på stemmetallene. Styrelsens indsigelser mod karakterisering var ikke argumenter for, at peptiderne ikke kunne karakteriseres. Det var konstateret, at de indsendte pakker ikke karakteriserede dem.

De analyse af FDAs orienteringsdokumenter udgivet af Bass, Bær & Sims opsummerer kerneresultatet: meningsfulde kvalitetsstandarder kan ikke udvikles, medmindre et stofs kemiske identitet er veletableret. FDA-personale rapporterede, at litteratur og kommercielle kilder ofte beskriver stoffer under det samme almindelige navn på trods af forskelle i aminosyresekvens, eller uden at afklare, om materialet er en fri base, et salt, or an ester — and noted that different salt and ester forms of the same active moiety can behave differently in physicochemical, toxicological, and pharmacokinetic terms.

The BPC-157 case is the sharpest illustration. FDA reported encountering multiple substances marketed under that single common name containing different active moieties, and observed that the common name does not follow established chemical nomenclature conventions. There may be, in the agency’s stated view, no reliable basis for assuming a given name always identifies the same structure and form.

Three further deficiencies recurred across the set:

• Critical quality attribute testing was thin. Nominations and public information frequently lacked data on peptide impurities, aggregates, microbial quality, and bacterial endotoxins — all relevant for injectable dosage forms.

• Method detail was insufficient. FDA stated it could not evaluate how identity, renhed, and impurities were measured from the materials provided. A percentage purity figure without a named chromatographic method and the supporting chromatograms is not an assessable claim.

• Impurity work was not comparative. What FDA wanted was a full impurity profile — identification, quantification, and control across batches and sources — rather than isolated residual values.

Immunogenicity risk threaded through the safety discussion, particularly for injected peptides where impurities and aggregates are not adequately controlled.

None of those four findings requires a novel scientific method. Each of them requires records that a synthesis organization either keeps or does not.

Domæne 1 — Identitet: Kan dine optegnelser bevise, hvilket molekyle du har lavet?

Identity is the domain FDA treated as foundational in its evaluation of 503A bulks list peptides, and the standard it applied is stricter than most certificates of analysis imply. A single mass confirmation for the intact molecule establishes molecular weight. It does not establish sequence, it does not distinguish an isomer, and it does not tell a reviewer whether the material is a free base or an acetate salt.

No single technique closes that gap. The frameworks converge on requiring orthogonal methods — separate techniques that could each independently fail, and that rest on different physical principles. The EMA synthetic-peptide guideline, for instance, expects identity to be supported by at least two orthogonal methods.

The last item is where identity documentation and process documentation meet. A sequence made by solid-phase synthesis with a particular coupling strategy has a predictable failure pattern — truncations, sletninger, epimerization at specific residues. A record that names the route makes those risks assessable. A record that lists only a final mass does not.

Domæne 2 — Renhed: Kan dit nummer gengives af en anden?

A purity percentage is the most quoted and least informative figure on a typical peptide CoA. It answers one question — what fraction of the ultraviolet-absorbing material in the sample corresponds to the main peak — and it is silent on several others that determine whether the number means anything.

Method purity is not the same as peptide content. Vand, modioner, resterende opløsningsmidler, and non-UV-absorbing contaminants sit outside what a chromatographic purity figure captures. A sample reported at 98% purity by area can contain meaningfully less peptide by mass once those components are accounted for. Reporting both, and labelling which is which, is the difference between a measurement and a marketing number.

Lot-to-lot consistency deserves separate mention because it is the claim most often asserted and least often evidenced in custom peptide synthesis documentation. Consistency is not a property of any single batch. It is a property of a data set — which means the evidence is a trend across lots against fixed criteria, not a certificate for the lot in hand. If a supplier cannot produce that trend, “lot-to-lot consistency” in a specification is a statement of intent rather than a demonstrated control.

Domæne 3 — Analysemetoder: Kunne en anmelder genopbygge din metode?

FDA’s stated complaint was not that the analytical results were wrong. It was that the materials did not provide enough method-specific information to judge whether the results were reliable. That distinction matters, because it means the fix is descriptive rather than experimental.

For each method used to support a specification, a reviewer needs enough detail to understand what was measured and to form a view on whether the method can do what it claims. What a method must demonstrate before its numbers are usable is set out in I Q2(R2) on the validation of analytical procedures, and the chromatographic parameters an implied method must state are defined in USP <621> Chromatography.

A useful test: hand the method section to a competent analyst who has never worked on the molecule and ask them to reproduce the run. If they cannot, the section is not finished. This is a lower bar than validation and it catches the majority of real gaps.

Domæne 4 — Peptid-urenhedsprofiler: Hvad FDA-peptidlisteprocessen forventer

This is where the July 2026 record is most specific and where threshold numeracy matters most.

Synthetic peptides sit in an unusual regulatory position. The EMA synthetic-peptide guideline states that synthetic peptides are fully or partially excluded from the scope of ICH Q3A and Q3B, ICH Q6A and Q6B, and ICH M7, and instead applies peptide-specific impurity thresholds anchored to the European Pharmacopoeia general monograph. FDA’s synthetic peptide guidance has treated ICH Q3A and Q3B as a general framework with peptide-specific modifications. Either way, the small-molecule impurity table does not apply unchanged, and a program should be able to state which framework it is following and why.

Reported tier details vary across secondary summaries of the July 2026 drafts, og den 2021 guidance was withdrawn with a reissue pending — so treat any single number here as framework-specific and verify the current document before you rely on it in a submission. The structural point is stable even though the numbers may shift: peptide-related impurities are governed by their own thresholds, and they are low.

What that means for the peptide impurity profile a program should hold:

The commercial argument for doing this work before anyone asks is straightforward. Impurity characterization is cheapest at the point when the chemistry is still being adjusted. Once a specification is fixed and a program has committed to a supplier, an unidentified impurity at 0.6% becomes a deviation, a retest, and possibly a reformulation of the control strategy. The peptide impurity profile FDA expects under current guidance is not new in kind; the July 2026 record simply made it unusually visible.

Domæne 5 — Indkøb: Kan du gå en batch tilbage til dens aminosyrer?

This is the domain that received the least public attention and carries the most unexamined risk. Compounding-list coverage focused on the peptide. FDA’s characterization questions, and the general expectations for peptide starting materials, reach all the way back to the amino acid derivatives, harpikser, and solvents that went into the synthesis.

USP General Chapter <1504> addresses quality attributes of starting materials for the chemical synthesis of therapeutic peptides and is intended to be used alongside the peptide drug substance chapter. It names the non-amino-acid-derivative impurity risks these materials carry: residual solvents and reagents left over from their own preparation, elemental impurities, and transmissible spongiform encephalopathy or bovine spongiform encephalopathy risk. ICH Q7 Chapter 7 sets the materials management baseline — each raw material batch recorded with manufacturer name, identitet, quantity, supplier, and supplier control number, purchased against agreed specifications, and traceable into the batches where it was used.

Two practical points. Først, the manufacturer of a critical material should always be known and documented — not just the distributor. Identity of the actual producer is what makes a supply risk assessable. Anden, change control is the part of supplier qualification most often left verbal. A written commitment to notify before a process or site change is what converts a supplier relationship into a managed one. Programs that outsource synthesis support with a peptide CRO services partner inherit that partner’s supply chain, so the same traceability questions apply one layer further up.

Domæne 6 — Tilsigtet Brug: Passer din specifikation til ruten og dosis?

Here the July 2026 record offers the clearest lesson about specifications generally. Every one of the seven peptides was evaluated for a specific proposed use. The committee that reviewed BPC-157 considered ulcerative colitis. Semax was reviewed for cerebral ischemia, migræne, and trigeminal neuralgia. Emideltide was assessed for opioid withdrawal, kronisk søvnløshed, and narcolepsy, and FDA’s stated concern included the absence of safety data for the subcutaneous route in particular.

That is not a detail of the compounding framework. It is the general principle: the specification follows the intended use, the route, and the dose — not the molecule name in isolation.

The EMA synthetic-peptide guideline makes the same point structurally. It applies to synthetic peptides used in a medicinal product, distinguishes research-use-only material from pharmaceutical material, expects the counterion to be identified with its stoichiometry, and expresses peptide content on a counterion-free, anhydrous basis within a mass-balance approach to content and purity. A material that is entirely adequate for in vitro screening can be inadequate for an injectable formulation, and the specification is where that difference lives.

The last row is deliberately uncomfortable. Being able to say “this material is qualified for X and would need Y before it could support Z” is more useful to a reviewer and a partner than a specification broad enough to permit everything and specific enough to prove nothing. It is also the record most often missing, because it requires a decision rather than a measurement. For teams designing peptide variants toward a target profile, the same logic applies one step earlier — read across the protein engineering lessons for peptide optimization to see how design intent constrains the quality attributes worth tracking from the first batch.

At score pakken, før en anden gør det

FDA’s four criteria give a program something better than a checklist: they imply a scoring rule that predicts which parts of a documentation package will be challenged. The criterion that receives the most attention publicly is characterization, but the one that sinks petitions is usually the weakest link rather than the average.

The scoring discipline that matters is not adding up the good rows. It is identifying the one domain where the program would have nothing to say if asked, and closing that gap first. Work on the strong domains is comfortable and mostly adds documentation weight; work on the weak domain is what changes the outcome.

A second practical step is to convert these tables into a vendor questionnaire and answer it as though it were being asked by someone else. Most programs find that the material they can produce readily — chromatograms, massespektre, CoAs — maps onto the domains they are already strong in, while the domains that depend on deliberate record-keeping, sourcing traceability and intended-use justification, require decisions they have not yet made. That asymmetry is predictable, and it is better found internally than during a review.

None of this depends on how the rulemaking concludes or what the February 2027 committee does with a further set of peptides. The record set described in this peptide documentation checklist is what any peptide program should be able to produce to describe its own material honestly — to a regulator, to a partner conducting due diligence, or to its own quality function during an investigation to which external review is a detail rather than the trigger.

Næste trin

If any of the six domains above came back thin, the useful next move is a technical review of the specific gaps rather than a general quality claim. MOL Changes works with development teams on exactly that: walking through an existing documentation package against identity, renhed, methodological, impurity, sourcing, and intended-use expectations, and identifying what a lot-specific data package would need to include to close the gap. If that would help your program, ask for a technical feasibility assessment and we will tell you plainly what your current records support, what they do not, and what it would take to get there.